seroneg
persist
infect
pi
calv
bovin
viral
diarrhea
viru
bvdv
subtyp
vaccin
four
modifi
live
viru
mlv
bvdv
vaccin
mannheimia
haemolytica
bacterintoxoid
nasal
swab
peripher
blood
leukocyt
pbl
collect
viru
isol
serum
collect
vaccin
test
bovin
bovin
viru
bovin
respiratori
syncyti
viru
brsv
antibodi
haemolytica
pasteurella
multocida
antibodi
detect
use
elisa
procedur
none
pi
calv
develop
mucos
diseas
md
mlv
vaccin
none
bvdv
pi
calv
seroconvert
mlv
vaccin
calv
receiv
mlv
vaccin
seroconvert
respect
typesubtyp
vaccin
calv
receiv
mlv
vaccin
noncytopath
ncp
subtyp
design
seroconvert
pi
calv
posit
bvdv
subtyp
pbl
nasal
swab
throughout
studi
calv
receiv
three
vaccin
known
strain
posit
sampl
vaccin
calv
day
pi
calv
respond
increas
haemolytica
antibodi
vaccin
compar
bvdv
neg
calv
receiv
haemolytica
vaccin
bovin
viral
diarrhea
viru
bvdv
present
us
countri
worldwid
bvdv
classifi
biotyp
base
presenc
absenc
visibl
cytopath
effect
infect
cell
cultur
cytopath
cp
noncytopath
ncp
also
genotyp
antigen
differ
separ
bvdv
type
differenti
subtyp
bvdv
respons
numer
clinic
syndrom
includ
acut
infect
well
condit
associ
immunosuppress
effect
viral
infect
fetal
infect
may
occur
suscept
cowsheif
develop
viremia
initi
acut
infect
sever
outcom
fetal
infect
depend
gestat
stage
fetu
expos
utero
infect
bovin
fetus
ncp
bvdv
day
may
caus
persist
infect
pi
fetu
remain
immunotoler
infect
bvdv
fetus
carri
term
remain
seroneg
infect
viru
shed
bvdv
throughout
lifetim
pi
calv
consid
princip
reservoir
expos
suscept
cattl
sever
clinic
form
bvdv
call
mucos
diseas
md
occur
cattl
calv
pi
bvdv
develop
md
subsequ
infect
relat
cp
bvdv
strain
postvaccin
reaction
resembl
md
occur
calv
receiv
modifi
live
viru
mlv
bvdv
vaccin
although
occurr
low
mlv
bvdv
vaccin
cattl
contain
cp
biotyp
one
vaccin
led
speculationinfer
pi
calv
receiv
mlv
bvdv
vaccin
develop
md
object
studi
determin
host
respons
pi
infect
calv
ncp
vaccin
mlv
vaccin
variou
bvdv
type
subtyp
determin
whether
pi
calv
could
develop
serum
antibodi
bacteri
immunogen
mannheima
haemolytica
bacterintoxoid
eight
calv
obtain
ranch
undergo
reproduct
loss
breed
herd
calv
born
march
april
identifi
pi
base
bvdv
posit
immunohistochemistri
test
us
sampl
sampl
sampl
sampl
sampl
sampl
sampl
sampl
sampl
brsv
sampl
ing
ear
notch
sampl
calv
deliv
facil
oklahoma
state
univers
isol
cattl
pen
contain
individu
water
calv
receiv
hay
grain
mixtur
feed
edta
contain
blood
tube
peripher
blood
leukocyt
pbl
prepar
nasal
swab
viral
isol
collect
serum
also
prepar
antibodi
test
viral
isol
viru
neutral
test
use
madindarbi
bovin
kidney
mdbk
cell
microtit
plate
use
quantit
viral
neutral
antibodi
bvdv
use
cp
singer
strain
tgac
cp
strain
cp
strain
type
viru
bovin
respiratori
syncyti
viru
brsv
previous
describ
plaqu
reduct
assay
plate
mdbk
monolay
use
quantit
bovin
herp
viru
antibodi
antibodi
haemolytica
whole
cell
haemolytica
leukotoxin
pasteurella
multocida
outer
membran
protein
omp
assay
elisa
test
viru
isol
pbl
nasal
swab
serum
attempt
describ
use
either
mdbk
bovin
turbin
bt
cell
substrat
bvdv
isol
subtyp
differenti
polymeras
chain
reaction
pcr
test
utr
region
sequenc
select
isol
mlv
vaccin
use
studi
contain
bvdv
brsv
vaccin
respect
bvdv
biotyp
cp
ncp
subgenotyp
cp
strain
cp
strain
vaccin
cp
singer
vaccin
ncp
subtyp
identifi
wrl
strain
vaccin
cp
nadl
strain
bacteri
vaccin
contain
haemolytica
bacterintoxoid
june
two
calv
receiv
one
four
mlv
vaccin
tabl
accord
label
instruct
calv
seroneg
day
select
calv
may
matern
antibodi
andor
brsv
day
tabl
pi
calv
receiv
haemolytica
bacterintoxoid
day
subcutan
rout
control
group
eight
healthi
bvdvfree
calv
hous
anoth
facil
receiv
vaccin
four
healthi
bvdvfree
calv
serv
nonvaccin
control
sampl
includ
pbl
nasal
swab
obtain
mlv
vaccin
calv
day
viral
isol
nasal
swab
viral
isol
also
collect
day
serum
antibodi
test
prepar
day
weekli
thereaft
day
none
pi
calv
develop
clinic
sign
md
studi
one
calf
h
receiv
vaccin
die
day
patholog
examin
reveal
sever
suppur
ulcer
enterocol
sampl
collect
prior
death
pbl
nasal
swab
well
organ
pool
necropsi
tissu
posit
ncp
bvdv
cp
strain
suggest
vaccin
origin
md
relat
viru
isol
pbl
nasal
swab
eight
pi
calv
posit
ncp
bvdv
day
prior
vaccin
pbl
posit
bvdv
throughout
studi
day
isol
pbl
subsequ
mlv
vaccin
remain
ncp
except
calf
receiv
vaccin
contain
cp
strain
cp
strain
isol
pbl
day
calf
b
receiv
vaccin
contain
two
differ
cp
strain
cp
strain
isol
pbl
day
calv
b
receiv
vaccin
contain
two
differ
cp
strain
cp
strain
isol
pbl
day
neither
calv
receiv
vaccin
contain
ncp
bvdv
cp
bvdv
strain
pbl
vaccin
nasal
swab
sampl
posit
postvaccin
day
bvdv
isol
ncp
day
cytopath
strain
found
nasal
swab
sever
calv
day
although
appear
cp
equivoc
presenc
strain
pbl
nasal
swab
indic
tabl
detect
day
sampl
isol
calv
receiv
mlv
vaccin
posit
pbl
andor
nasal
swab
day
none
sampl
two
calv
receiv
ncp
posit
like
ncp
posit
along
cp
isol
attempt
made
separ
clone
cp
ncp
bvdv
posit
sampl
antibodi
titer
virus
list
tabl
vaccin
calv
develop
detect
antibodi
titer
vaccin
calv
respond
bvdv
antibodi
respect
bvdv
subtyp
vaccin
except
calf
h
receiv
vaccin
die
day
low
antibodi
tier
titer
signific
fourfold
greater
increas
titer
day
calv
b
respond
antibodi
expect
vaccin
contain
strain
calv
c
respond
antibodi
vaccin
contain
calv
e
f
receiv
vaccin
contain
ncp
undesign
develop
antibodi
one
calf
surviv
throughout
studi
receiv
vaccin
contain
develop
antibodi
vaccin
mlv
vaccin
stimul
antibodi
twofold
greater
day
calv
one
calf
b
matern
antibodi
respond
increas
antibodi
calf
remain
seroneg
vaccin
four
eight
calv
respond
increas
brsv
antibodi
fourfold
greater
low
tabl
mean
mean
ratio
valuebaselin
alpha
use
make
comparison
due
small
sampl
size
larg
standard
error
differ
ratio
signific
day
antibodi
haemolytica
leukotoxin
haemolytica
whole
cell
antigen
non
pi
healthi
vaccin
calv
significantli
higher
ratio
antibodi
compar
pi
calv
nonvaccin
control
increas
p
multocida
antibodi
expect
vaccin
contain
p
multocida
immunogen
result
studi
support
studi
wherebi
pi
bvdv
cattl
abl
respond
bvdv
immunogen
specif
bvdv
induc
immunotoler
present
studi
uniqu
cite
studi
perform
without
bvdv
strain
pi
calv
identifi
typesubtyp
studi
use
genet
differ
detect
pcr
sequenc
report
mcclurkin
et
al
report
vm
mc
strain
induc
pi
calv
suscept
fetus
subtyp
strain
later
subtyp
vm
bvdv
subtyp
mc
strain
known
pi
calv
studi
develop
antibodi
viral
bacteri
agent
studi
four
pi
bull
expos
develop
neutral
antibodi
viru
rang
none
six
pi
bull
inject
intraven
homolog
bvdv
develop
bvdv
antibodi
bolin
et
al
vaccin
twoyearold
steer
pi
bvdv
nebraska
strain
later
determin
three
vaccin
mlv
bvdv
cp
nadl
later
determin
mlv
bvdv
cp
singer
later
determin
kill
vaccin
bvdv
singer
clinic
sign
md
observ
six
week
vaccin
howev
md
develop
pi
calv
expos
cp
bvdv
strain
tgac
later
determin
serum
collect
necropsi
nine
pi
anim
indic
pi
anim
remain
seroneg
pi
strain
nebraska
bvdv
later
determin
calv
titer
strain
bvdv
later
determin
calv
titer
singer
strain
bvdv
later
determin
anoth
studi
bolin
report
three
cow
pi
nebraska
bvdv
later
determin
strain
vaccin
mlv
vaccin
contain
cp
bvdv
nadl
strain
later
determin
sampl
collect
three
week
postvaccin
pi
anim
antibodi
titer
bvdv
strain
later
determin
bvdv
singer
strain
later
determin
pi
calv
remain
seroneg
nebraska
tgan
later
determin
studi
perform
without
knowledg
bvdvsubtyp
statu
strain
pi
vaccin
challeng
strain
current
knowledg
variou
bvdv
subtyp
allow
interpret
result
prior
studi
particularli
relat
serum
antibodi
respons
heterolog
bvdv
strain
pi
anim
houe
heron
report
pi
calv
respond
cellular
immun
respons
includ
cutan
tuberculin
test
john
diseas
immun
also
pi
calv
becam
sensit
skin
sensit
agent
dncb
develop
serum
antitoxin
tetanu
immun
studi
also
report
pi
calv
respons
antigen
significantli
differ
compar
non
pi
calv
thu
pi
calv
respond
nonbvdv
antigen
cellular
humor
respons
howev
present
studi
pi
calv
fail
immunolog
respond
haemolytica
bacterintoxoid
bvdv
known
caus
immunosuppress
pi
calv
may
remain
immunotoler
antigen
other
result
current
studi
confirm
pi
calv
respond
heterolog
bvdv
strain
particularli
vaccin
strain
initi
attempt
elimin
pi
bvdv
anim
util
presenc
bvdv
antibodi
declar
anim
non
pi
anim
erron
approach
detect
elimin
pi
anim
review
diagnost
laboratori
access
found
pi
calv
serum
antibodi
bvdv
isol
subsequ
found
base
pcr
calv
later
found
vaccin
mlv
vaccin
contain
nadl
strain
anoth
studi
pi
calf
strain
develop
serum
antibodi
singer
strain
follow
vaccin
mlv
singer
vaccin
result
two
studi
current
studi
underscor
point
presenc
bvdv
antibodi
loss
matern
antibodi
necessarili
indic
non
pi
statu
abil
mlv
bvdv
vaccin
viru
shed
pi
calv
support
studi
nasal
swab
pbl
collect
postvaccin
contain
calv
receiv
contain
vaccin
interv
detect
day
potenti
new
bvdv
strain
could
develop
pi
calv
vaccin
mlv
vaccin
contain
heterolog
bvdv
ridpath
bolin
report
ncp
cp
pair
isol
anim
die
md
three
month
vaccin
mlv
nadl
vaccin
cp
strain
insert
genom
sequenc
vaccin
viru
thu
md
may
result
recombin
pi
viru
exogen
viru
vaccin
strain
current
isol
studi
examin
possibl
genet
recombin
bovin
respiratori
diseas
brd
includ
ship
fever
bacteri
pneumonia
caus
haemolytica
p
multocida
occasion
haemophilu
somnu
bacteri
pneumonia
associ
stress
may
often
predispos
virus
brsv
bovin
coronavirus
bovin
adenovirus
pi
bvdv
anim
shed
viru
may
render
contact
cattl
suscept
bacteri
infect
bvdv
immunosuppress
reduc
lymphocyt
neutrophil
macrophag
function
pneumonia
may
also
found
pi
bvdv
calv
necropsi
studi
pi
calv
singl
herd
move
feedlot
observ
time
pi
calv
gross
pneumon
lesion
necropsi
mild
md
lesion
mcclurkin
et
al
also
report
pi
calv
expos
haemolytica
aerosol
one
four
calv
die
acut
pasteurellosi
within
three
day
three
calv
becam
febril
eventu
recoveri
increas
haemolytica
antibodi
titer
reduc
immun
respons
haemolytica
immunogen
studi
suggest
pi
calf
may
suscept
virul
haemolytica
bacteri
respiratori
pathogen
conclus
vaccin
pi
calv
heterolog
bvdv
strain
induc
md
interv
studi
calv
mount
immun
respons
detect
serum
antibodi
bvdv
subtyp
vaccin
studi
calv
continu
shed
viru
includ
heterolog
strain
howev
durat
detect
shed
ceas
end
studi
pi
calv
respond
bvdv
vaccin
immunogen
respond
well
healthi
non
pi
calv
haemolytica
vaccin
